Journal
Therapeutic Advances in Neurological Disorders
Publication Date
1-24-2023
Volume
16
First Page
17562864221149781
Document Type
Open Access Publication
DOI
10.1177/17562864221149781
Rights and Permissions
Goedeker NL, Dharia SD, Griffin DA, Coy J, Truesdale T, Parikh R, Whitehouse K, Santra S, Asher DR, Zaidman CM. Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221149781. doi: 10.1177/17562864221149781.© The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Goedeker, Natalie L; Dharia, Sachi D; Griffin, Danielle A; Coy, Jesantha; Truesdale, Todd; Parikh, Rajan; Whitehouse, Kasen; Santra, Sourav; Asher, Damon R; and Zaidman, Craig M, "Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy." Therapeutic Advances in Neurological Disorders. 16, 17562864221149781 (2023).
https://digitalcommons.wustl.edu/oa_4/4323
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
